Journal Scans
Stanford V Program for Locally Extensive and Advanced Hodgkin Lymphoma: The Memorial Sloan-Kettering Cancer Center Experience
Stanford V Efficacy in Advanced Hodgkin’s Lymphoma
SM Edwards-Bennett, LM Jacks, CH Moskowitz, EJ Wu, Z Zhang, A Noy, CS Portlock, DJ Straus, AD Zelenetz, J Yahalom
20100201
2010 Mar 1
Ann Oncol
Stanford V Program for Locally Extensive and Advanced Hodgkin Lymphoma: The Memorial Sloan-Kettering Cancer Center Experience
Ann Oncol. 2010 Mar 1;21(3):574-581, SM Edwards-Bennett, LM Jacks, CH Moskowitz, EJ Wu, Z Zhang, A Noy, CS Portlock, DJ Straus, AD Zelenetz, J Yahalom
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Patients with advanced-stage Hodgkin’s lymphoma have several chemotherapy options, but until mature results of ongoing phase III trials are available, the optimal regimen remains unclear. In the meantime, the best clinical outcomes have been obtained with escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V (nitrogen mustard, doxorubicin, bleomycin, vincristine, vinblastine, etoposide, and prednisone, followed by involved-field...
